( To visit the site: Click Here )
Tarceva 150 mg
|Pharmaceutical form||30 Tabs|
|Indications||- Non Small Cell Lung Cancer (NSCLC)
- First-line treatment of patients with locally advanced or metastatic (NSCLC) with EGFR activating mutations.
- As monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-line chemotherapy.
- Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
- Pancreatic cancer
- Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer